Top Drug Stocks are MYL, XNPT, SNSS, SOMX

XenoPort, Inc. (NASDAQ:XNPT) is amongst the top gainer in the early few hours. The stock has spurted 4.74% and is trading at $8.40 with an unusual high volume of 4.97 million shares. The stock has a 52-week range of $6.39-$25.42. XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.

Subscribe to daily free stock newsletter by visiting:  http://www.pennystockpickreport.com/

Mylan Inc. (NASDAQ:MYL) climbed up 5.30% to $20.45 on an unusual high volume of 16.10 million shares. The stock today also touched a new 52 week high at $21.03. The company reaffirmed fiscal 2010 earnings (EPS) guidance of $1.50-$1.70 per share. The Company projects revenues in excess of $8.5 billion in fiscal 2013, representing a top-line CAGR of 15%, from fiscal 2010. The Company is also projecting EPS in excess of $2.75 in fiscal 2013, which represents a CAGR of 20%. Additionally, the Company expects it will be able to deliver EPS in excess of $2 in fiscal 2011. According to Reuters Estimates, analysts are expecting the Company to report EPS of $1.54 for fiscal 2010; EPS of $1.78 for fiscal 2011; EPS of $2.07 on revenues of $6.4 billion for fiscal 2013.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rallied 5.20% to $0.937 on an unusual volume of 4.28 million shares. The company announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response to proposed plans for further development of voreloxin in the treatment of AML. Based on the development clarity achieved as a result of these meetings, Sunesis intends to proceed with its plan to conduct a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. This trial will evaluate the overall survival of voreloxin in combination with cytarabine, a widely used chemotherapy in AML, compared to cytarabine with placebo, in patients with relapsed or refractory AML. Sunesis anticipates initiating this multi-national, Phase 3 trial in the second half of 2010.

Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) is amongst the top gainers in the early hours with a volume of 1.29 million shares and zoomed 4.89% at $3.65. The stock has a 52-week range of $0.17-$4.80. So far in the last six months trade the stock has rallied over 56%. Somaxon Pharmaceuticals, Inc. (Somaxon) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The Company is focused on the development of Silenor.

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers a stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks ,Drug Stocks , top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.